RA
CTKB icon

Royce & Associates’s Cytek Biosciences CTKB Stock Holding History

Royce & Associates’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.22M Buy
2,081,579
+439,211
+27% +$1.87M 0.07% 395
2026
Q1 		$7.18M Sell
1,642,368
-50,289
-3% -$237K 0.07% 407
2025
Q4 		$8.55M Sell
1,692,657
-70,605
-4% -$328K 0.09% 356
2025
Q3 		$6.12M Buy
1,763,262
+373,456
+27% +$1.4M 0.06% 426
2025
Q2 		$4.73M Buy
1,389,806
+823,987
+146% +$2.75M 0.05% 469
2025
Q1 		$2.27M Buy
565,819
+95,000
+20% +$492K 0.02% 571
2024
Q4 		$3.06M Buy
470,819
+289,425
+160% +$1.72M 0.03% 562
2024
Q3 		$1M Buy
181,394
+61,916
+52% +$351K 0.01% 730
2024
Q2 		$667K Buy
119,478
+108,128
+953% +$649K 0.01% 765
2024
Q1 		$76.2K Buy
+11,350
New +$89.8K ﹤0.01% 864
2023
Q4 		– Sell
-87,489
Closed -$483K – 882
2023
Q3 		$483K Buy
87,489
+15,209
+21% +$122K ﹤0.01% 815
2023
Q2 		$617K Buy
72,280
+27,866
+63% +$250K 0.01% 811
2023
Q1 		$408K Buy
+44,414
New +$478K ﹤0.01% 858

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royce & Associates's CTKB Position: Q2 2026 in Review

Royce & Associates increased its Cytek Biosciences (CTKB) stake by 27% in Q2 2026, buying an estimated $1.87M and bringing the position to 2,081,579 shares worth $9.22M. The position accounts for 0.07% of the portfolio, ranked #395.

Royce & Associates first reported a position in CTKB in Q1 2023 and has held it in 13 quarters since. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Royce & Associates held 2,081,579 shares of Cytek Biosciences worth $9.22M as of Q2 2026.
  • Royce & Associates bought 439,211 Cytek Biosciences shares in Q2 2026, an estimated $1.87M.
  • Cytek Biosciences made up 0.07% of Royce & Associates's portfolio in Q2 2026, its #395 holding.
  • Royce & Associates first reported a position in Cytek Biosciences in Q1 2023 and has held it in 13 quarters since.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.